Imprimis; Priming the Pumps for a Big 2019

If you've been paying attention to me, you know that I've been very bullish on Imprimis Pharmaceuticals (IMMY). In particular, my thinking was that...

Imprimis Pharmaceuticals Announces Third Quarter 2018 Results

SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the third quarter 2018. Third Quarter 2018 and...

October Review, Earnings Preview

October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from...

Imprimis Pharmaceuticals’ Subsidiary Melt Pharmaceuticals Initiates Clinical Development Program for its Patented Non-Opioid and...

Tailwinds' Take: Melt is potentially the hidden gem in the Imprimis portfolio. I don't think the market equates any significant value to this subsidiary,...

Imprimis Primed For Big Rally

On Thursday evening, one of Tailwinds' readers, sensing a rally, asked me which stock in the TW universe had the following three characteristics: Down...

Imprimis Pharmaceuticals Announces Second Quarter 2018 Results

SAN DIEGO, Aug. 6, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the second quarter 2018. Notable Highlights from the Second Quarter of 2018: ...

Imprimis Announces Multi-Center Clinical Trial for Dropless® TriMoxi™ (Triamcinolone Acetonide-Moxifloxacin for injection) Formulation in...

SAN DIEGO, Aug. 1, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) through its ImprimisRx ophthalmology business today announced its Canadian partner, Advanced Dosage Forms Inc., will...

ImprimisRx’s Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract...

SAN DIEGO, May 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.'s (NASDAQ: IMMY) ophthalmology compounding division, ImprimisRx, is pleased to announce the findings from a study published...